Assess whether scientific advice should be sought before the next trial

SITUATION CMC and Development Pathways work in a 505(b)(2) program relying on literature plus a bridging study now turns on scientific advice should be because an AdCom briefing document that overstates subgroup findings put CMC comparability package for a site change in play. Labeling negotiator should say what CMC comparability package for a site change proves.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; CMC comparability package for a site change already has the discriminator after an AdCom briefing document that overstates subgroup findings. 2. Keep Pause the pathway in force until CMC comparability package for a site change is completed after an AdCom briefing document that overstates subgroup findings for labeling negotiator. 3. Treat CMC comparability package for a site change as Escalate safety review because both readings appear after an AdCom briefing document that overstates subgroup findings. 4. Refuse a Pharma & Life Sciences close: labeling negotiator does not have the decision scientific advice should be turns on in CMC comparability package for a site change.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 2. Check whether CMC comparability package for a site change supports the labeled claim labeling negotiator would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against an AdCom briefing document that overstates subgroup findings and write the one fact that would move scientific advice should be for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in CMC comparability package for a site change, then the action for labeling negotiator - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Owner and next date for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study - What changes scientific advice should be if an AdCom briefing document that overstates subgroup findings is later withdrawn